Daniel Lawrence Rader

US Patent:

7008776, Mar 7, 2006

Filed:

Mar 26, 1999

Appl. No.:

09/277401

Inventors:

Michael Jaye - Glenside PA, US
Kim-Anh Thi Doan - Spring City PA, US
John A. Krawiec - Gulph Mills PA, US
Kevin J. Lynch - Gurnee IL, US
Dilip V. Amin - Lansdale PA, US
Victoria J. South - Collegeville PA, US
Dawn Marchadier - Sickelerville NJ, US
Cyrille Maugeais - Philadelphia PA, US
Daniel J. Rader - Collegeville PA, US

Assignee:

Aventis Pharmaceuticals Inc. - Bridgewater NJ
The Trustees of the University of Pennsylvania - Philadelphia PA

International Classification:

G01N 33/573
C12N 9/20

US Classification:

435 74, 435198

Abstract:

The present invention relates to compositions for use in raising or lowering the level of LIPG polypeptide in a patient. Embodiments of the composition include compositions comprising: an anti-sense nucleic acid; a neutralizing antibody; an intracellular binding protein; an inhibitor which inhibits the enzymatic activity of LIPG polypeptide; an inhibitor which inhibits the expression of LIPG gene; a ribozyme; an LIPG polypeptide; an enhancer which increases the enzymatic activity of LIPG polypeptide; or an enhancer which increases the expression of LIPG gene. The invention relates also to methods for using the above compositions. In addition, the invention relates to a method for diagnosing a predisposition to lower cholesterol, a method for determining whether a test compound can inhibit the enzymatic reaction between LIPG polypeptide and HDL cholesterol, and methods for determining whether a test compound can enhance the enzymatic reaction between LIPG polypeptide and LDL or VLDL cholesterol.

US Patent:

7932268, Apr 26, 2011

Filed:

Mar 7, 2005

Appl. No.:

10/591923

Inventors:

Daniel J. Rader - Philadelphia PA, US

Assignee:

The Trustees of the University of Pennsylvania - Philadelphia PA

International Classification:

A61K 31/445

US Classification:

514321, 514325

Abstract:

The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.

US Patent:

8618135, Dec 31, 2013

Filed:

Mar 11, 2011

Appl. No.:

13/046118

Inventors:

Daniel J. Rader - Philadelphia PA, US

Assignee:

The Trustees of the University of Pennsylvania - Philadelphia PA

International Classification:

A61K 31/445
A61K 31/501
A61K 31/52

US Classification:

514321, 514325, 51425203, 51425503, 51426322

Abstract:

The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.

US Patent:

20050244892, Nov 3, 2005

Filed:

Feb 28, 2005

Appl. No.:

11/068806

Inventors:

Mitchell Lazar - Gladwyne PA, US
Daniel Rader - Philadelphia PA, US
Muredach Reilly - Philadelphia PA, US

International Classification:

G01N033/53

US Classification:

435007100

Abstract:

The risk or progression of cardiovascular disease and coronary artery disease is assessed in a mammalian subject by measuring the level or concentration of circulating serum resistin in a subject and comparing the measured level to resistin levels within a standardized or standard population. Methods of treating cardiovascular diseases and/or inflammatory disorders involve administering to a patient a composition that can reduce the circulating levels of resistin.

US Patent:

20060088504, Apr 27, 2006

Filed:

Oct 19, 2005

Appl. No.:

11/254195

Inventors:

Michael Jaye - Glensdale PA, US
Kim-Anh Doan - Spring City PA, US
John Krawiec - Gulph Mills PA, US
Kevin Lynch - Gurnee IL, US
Dilip Amin - Lansdale PA, US
Victoria South - Collegeville PA, US
Dawn Marchadier - Sicklerville NJ, US
Cyrille Maugeais - Philadelphia PA, US
Daniel Rader - Collegeville PA, US

Assignee:

Aventis Pharmaceuticals Inc. - Bridgewater NJ

International Classification:

C12Q 1/68
A61K 9/127
A61K 48/00
C12N 15/86
C12N 15/88

US Classification:

424093200, 514044000, 424450000, 435456000, 435458000, 435006000

Abstract:

Compositions and methods for raising the level of HDL cholesterol and apolipoprotein AI in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in a patient, including compositions and methods which effect the expression of a gene, LIPG, which encodes a lipase enzyme that is a member of the triacylglycerol lipase family or which effect the enzymatic activity of the enzyme.

US Patent:

20090208479, Aug 20, 2009

Filed:

Aug 25, 2008

Appl. No.:

12/197970

Inventors:

Michael Jaye - Glenside PA, US
Kim-Anh Thi Doan - Spring City PA, US
John A. Krawiec - Gulph Mills PA, US
Kevin J. Lynch - Gurnee IL, US
Dilip V. Amin - Lansdale PA, US
Victoria J. South - Collegeville PA, US
Dawn Marchadier - Sicklerville NJ, US
Cyrille Maugeais - Philadelphia PA, US
Daniel J. Rader - Collegeville PA, US

International Classification:

A61K 38/46
C12Q 1/60

US Classification:

424 946, 435 11

Abstract:

Compositions and methods for raising the level of HDL cholesterol and apolipoprotein AI in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in a patient, including compositions and methods which effect the expression of a gene, LIPG, which encodes a lipase enzyme that is a member of the triacylglycerol lipase family or which effect the enzymatic activity of the enzyme.

US Patent:

20110110924, May 12, 2011

Filed:

Sep 2, 2010

Appl. No.:

12/874305

Inventors:

Mitchell A. Lazar - Gladwyne PA, US
Daniel J. Rader - Philadelphia PA, US
Muredach P. Reilly - Philadelphia PA, US

Assignee:

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA - Philadelphia PA

International Classification:

A61K 39/395
G01N 33/566
A61P 9/10

US Classification:

4241301, 436501

Abstract:

The risk or progression of cardiovascular disease and coronary artery disease is assessed in a mammalian subject by measuring the level or concentration of circulating serum resistin in a subject and comparing the measured level to resistin levels within a standardized or standard population. Methods of treating cardiovascular diseases and/or inflammatory disorders involve administering to a patient a composition that can reduce the circulating levels of resistin.

US Patent:

20120138784, Jun 7, 2012

Filed:

Jan 13, 2012

Appl. No.:

13/350207

Inventors:

Daniel J. Rader - Philadelphia PA, US
Jeffrey T. Billheimer - West Chester PA, US

International Classification:

H01J 49/26
G01T 1/00

US Classification:

250282, 250395

Abstract:

Methods and compositions for the in vivo measurement of reverse cholesterol transport are provided.